Chronic ischemic wounds represent a major unmet medical need whose prevalence is increasing at an alarming rate. Common in diabetes 15% of diabetic patients develop a lower limb ulcer with 12-24% of those patients requiring an amputation.

Although the importance of treating the underlying ischemic cause is widely recognized, only Cellarium™ has the ability to significantly improve wound management by regenerating both tissue and vasculature simultaneously.

Delivered as a hydrogel dressing, Cellarium™ has demonstrated unprecedented revascularization in preclinical models of severe vascular insufficiency. Because the platform provides vascularization concurrent with tissue building, critical surface defects previously unresponsive or too vast for treatment can now be addressed clinically.